Table 2.
Thirty-day postoperative complications and in-hospital mortality among lung cancer resection patients.
| Postoperative Complications | Year | p-Value (Comparison between the 3 Years) | 2020 SARS-CoV-2 Patients | 2020 non-SARS-CoV-2 Patients | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2018 | 2019 | 2020 | Characteristics | p-Value (Comparison with 2019) | Characteristics | p-Value (Comparison with 2019) | p-Value (Comparison with 2020 SARS-CoV-2) | ||
| Hospitalized patients with lung cancer resection (n) | 12,153 | 12,227 | 11,634 | 51 | 11,583 | ||||
| Postoperative complications÷Pneumonia (%) | 15.7 * | 15.4 | 14.7 | 0.0805 | 60.8 | <0.0001 | 14.5 | 0.0592 | <0.0001 |
| Acute respiratory distress syndrome (%) | 7.7 * | 6 | 6.2 | <0.0001 | 29.4 | <0.0001 | 6.1 | 0.8522 | <0.0001 |
| Bleeding (%) | 8.7 | 9.6 | 9.5 | 0.0397 | 5.9 | 0.3671 | 9.5 | 0.7492 | 0.3803 |
| Respiratory failure %) | 13.8 * | 12.3 * | 11.3 | <0.0001 | 49 | <0.0001 | 11.1 | 0.0067 | <0.0001 |
| Heart failure (%) | 2.6 * | 2.5 | 2.2 | 0.0802 | 5.9 | 0.1414 | 2.2 | 0.0756 | 0.1026 |
| Acute renal failure (%) | 5.5 * | 5.1 | 4.7 | 0.0146 | 17.7 | 0.0010 | 4.6 | 0.0987 | 0.0005 |
| Phlebitis (%) | 1.6 | 1.6 | 1.6 | 0.9476 | 3.9 | 0.1926 | 1.6 | 0.9193 | 0.1897 |
| Pulmonary embolism (%) | 1.2 | 1.2 | 1.3 | 0.6432 | 3.9 | 0.1341 | 1.3 | 0.5542 | 0.1492 |
| Infectious complications (including sepsis) (%) | 12.7 * | 11.6 * | 10.3 | <0.0001 | 29.4 | <0.0001 | 10.2 | 0.0005 | <0.0001 |
| Severe complications a (%) | 30.6 * | 29 * | 27.2 | <0.0001 | 74.5 | <0.0001 | 27 | 0.0005 | <0.0001 |
| Clavien Dindo complications b (%) | 21.9 * | 20.0 * | 18.3 | <0.0001 | 64.7 | <0.0001 | 18.1 | 0.0002 | <0.0001 |
| Transfer to intensive care unit (%) | 22.8 | 22 ‡ | 23.3 | 0.0717 | 58.8 | <0.0001 | 23.1 | 0.0483 | <0.0001 |
| In-hospital mortality(%) | 2.6 * | 2 | 2.1 | 0.0024 | 21.6 | <0.0001 | 2 | 0.7079 | <0.0001 |
a: Having at least one of the following complications during the surgery stay or within the first 30 days after the operation: pneumonia, acute respiratory distress syndrome, respiratory failure, heart failure, acute renal failure, infectious complications, pulmonary embolism. b: Severe complications classified as grade III and IV in the Clavien Dindo classification (admission to ICU for more than 48 h, surgical revision or dialysis); * significantly more frequent compared to 2020 (p < 0.05); ‡ significantly less frequent compared to 2020 (p < 0.05).